Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bulleyaconitine is a diterpene alkaloid naturally derived from the plant *Aconitum bulleyanum*. It is primarily utilized in China as a non-narcotic analgesic and anti-inflammatory agent for the management of chronic pain conditions, including rheumatoid arthritis, osteoarthritis, and various neuropathic pain syndromes. The drug's mechanism of action involves the potent inhibition of voltage-gated sodium channels, which suppresses the generation and conduction of nerve impulses in pain pathways. Additionally, bulleyaconitine has been shown to stimulate the release of endogenous opioid peptides such as dynorphin A and modulate the reuptake of monoamine neurotransmitters like norepinephrine and serotonin. It is commonly formulated as soft capsules for oral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bulleyaconitine.